Adult diffuse IDH-wildtype lower-grade gliomas with PDGFRA gain/amplification should be upgraded as glioblastoma

Journal of Neuropathology & Experimental Neurology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 16, 2025

Abstract We explored the prognostic significance of platelet-derived growth factor receptor α (PDGFRA) gain/amplification in grade 2-4 adult gliomas to assess its value as an upgrading indicator. Fluorescence situ hybridization was performed detect PDGFRA 321 glioma specimens from Sun Yat-sen University Cancer Center (SYSUCC). Data 1934 cases with available next-generation sequencing results The Genome Atlas (TCGA) and cBioPortal were also analyzed. Of gliomas, 12.15% (39/321), 8.76% (93/1062), 6.88% (60/872) had SYSUCC, TCGA, cohorts, respectively. Grade 4 glioblastomas a greater rate than lower-grade (LGGs) all cohorts (all P < .05). associated older age, World Health Organization grade, isocitrate dehydrogenase (IDH)-wildtype, intact 1p/19q, telomerase reverse transcriptase promoter-wildtype, Ki67 index, epidermal amplification, chromosome 7+/10− alterations. predicted poor overall survival (OS) particularly IDH-wildtype LGGs, OS worse PDGFRA-amplified LGGs (P = .031) SYSUCC .026) cohorts. diffuse may serve

Язык: Английский

Tumor-treating fields in cancer therapy: advances of cellular and molecular mechanisms

Clinical & Translational Oncology, Год журнала: 2024, Номер unknown

Опубликована: Июнь 17, 2024

Язык: Английский